Attention: This platform is in beta mode. Expect some changes and adjustments.

AI Market Mood: Stock Dashboard

FULC


Fundamental

Company: Fulcrum Therapeutics Inc
Sector: Healthcare
Industry: Biotechnology
Country: USA
Exchange: NASD
Index: RUT
P/E: -
EPS (ttm): -0.31
Insider Own: 15.71%
Shs Outstand: 53.94M
Perf Week: -5.89%
Market Cap: 208.13M
Forward P/E: -
EPS next Y: -1.05
Insider Trans: 0.00%
Shs Float: 45.46M
Perf Month: -17.90%
Income: -17.91M
PEG: -
EPS next Q: -0.28
Inst Own: 91.15%
Short Float: 10.28%
Perf Quarter: 19.09%
Sales: 80.87M
P/S: 2.57
EPS this Y: 90.67%
Inst Trans: -11.72%
Short Ratio: 5.32
Perf Half Y: -57.18%
Book/sh: 4.77
P/B: 0.81
EPS next Y Percentage: -610.11%
ROA: -6.42%
Short Interest: 4.67M
Perf Year: -46.56%
Cash/sh: 4.77
P/C: 0.81
EPS next 5Y: 10.37%
ROE: -6.99%
52W Range From: 2.86
52W Range To: 13.70
Perf YTD: -17.90%
Dividend Est.: -
P/FCF: -
EPS past 5Y: 1.09%
ROI: -6.78%
52W High: -71.84%
Beta: 2.03
Dividend TTM: -
Quick Ratio: 18.44
Sales past 5Y: -1.37%
Gross Margin: 97.79%
52W Low: 34.91%
ATR (14): 0.27
Dividend Ex-Date: -
Current Ratio: 18.44
EPS Y/Y TTM: 82.81%
Oper. Margin: -35.11%
RSI (14): 39.78
Volatility W: 6.12%
Volatility M: 6.30%
Employees: 76
Debt/Eq: 0.04
Sales Y/Y TTM: 2987.86%
Profit Margin: -22.15%
Recom: 2.57
Target Price: 5.67
Option/Short: Yes / Yes
LT Debt/Eq: 0.03
EPS Q/Q: 10.53%
Payout: -
Rel Volume: 0.33
Prev Close: 3.96
Sales Surprise: -
EPS Surprise: 11.68%
Sales Q/Q: -100.00%
Earnings: Nov 13 BMO
Avg Volume: 879.43K
Price: 3.86
SMA20: -8.81%
SMA50: -6.16%
SMA200: -34.47%
Trades:
Volume: 195,955
Change: -2.56%

Technical:


Latest News:

ExxonMobil enlists Fulcrum LNG to develop natural gas resources offshore Guyana somewhat bullish
XOM

Summary: ExxonMobil enlists Fulcrum LNG to assist in developing a natural gas processing facility offshore Guyana with an estimated investment of $10-15 billion.

Full article
2024-06-24T22:28:43Z
The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and ... somewhat bullish
NVAX FULC MRNA BMY

Summary: Novavax, Inc. and Fulcrum Therapeutics, Inc. have surged on signing collaborations and licensing agreements with Sanofi, while Moderna, Inc. faces setback due to FDA delaying the review timeline for its mRNA-based RSV vaccine. Bristol Myers announced the FDA accelerated approval of Breyanzi for expanded treatment options.

Full article
2024-05-17T13:48:47Z
Buy stocks Tuesday like Nvidia - CNBC neutral
TSLA CG FULC REGN NVDA SAM RBLX GXO AAPL HUYA WFRD ATO PLNT FTHC VTEX XPRO EIX CRH SRPT AMZN WDC STX EW

Summary: Multiple calls on Wall Street for various companies including Tesla, CG Oncology, Fulcrum Therapeutics, Regeneron, Nvidia, Boston Beer, Roblox, GXO Logistics, Apple, Huya, Weatherford, Atmos Energy, Planet Fitness, Fortrea Holdings, Vtex, Expro, Edison International, CRH, Sarepta, Amazon, Western Digital, Seagate, and Edwards Lifesciences.

Full article
2024-05-14T16:48:58Z